Kurkinen M. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease. Adv Clin Exp Med. 2023;32(9):943–7.

Article  PubMed  Google Scholar 

Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(2):73–88.

Article  PubMed  Google Scholar 

Kepp KP, Sensi SL, Johnsen KB, Barrio JR, Hoilund-Carlsen PF, Neve RL, et al. The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes. J Alzheimers Dis. 2023;94(2):497–507.

Article  CAS  PubMed  Google Scholar 

Espay AJ, Kepp KP, Herrup K. Lecanemab and donanemab as therapies for Alzheimer’s disease: an illustrated perspective on the data. eNeuro. 2024;11(7).

Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3):843–54.

Article  PubMed  PubMed Central  Google Scholar 

Femminella GD, Edison P. Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimer’s Dement J Alzheimer’s Assoc. 2014;10(1 Suppl):S55-61.

Google Scholar 

Bailly M, Destrieux C, Hommet C, Mondon K, Cottier JP, Beaufils E, et al. Precuneus and cingulate cortex atrophy and hypometabolism in patients with Alzheimer’s disease and mild cognitive impairment: MRI and (18)F-FDG PET quantitative analysis using FreeSurfer. Biomed Res Int. 2015;2015:583931.

Article  PubMed  PubMed Central  Google Scholar 

Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32(3):412–9.

Article  CAS  PubMed  Google Scholar 

Yonamine CY, Michalani MLE, Moreira RJ, Machado UF. Glucose transport and utilization in the hippocampus: from neurophysiology to diabetes-related development of dementia. Int J Mol Sci. 2023;24(22).

de la Monte SM. Conquering insulin network dysfunctions in Alzheimer’s disease: where are we today? J Alzheimers Dis. 2024;101(s1):S317–43.

Article  PubMed  PubMed Central  Google Scholar 

Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Hypometabolism, Alzheimer’s disease, and possible therapeutic targets: an overview. Cells. 2023. https://doi.org/10.3390/cells12162019.

Article  PubMed  PubMed Central  Google Scholar 

Hoyer S. The abnormally aged brain. Its blood flow and oxidative metabolism. A review—Part II. Arch Gerontol Geriatr. 1982;1(3):195–207.

Article  CAS  PubMed  Google Scholar 

Hoyer S, Oesterreich K, Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol. 1988;235(3):143–8.

Article  CAS  PubMed  Google Scholar 

Hoyer S. Senile dementia and Alzheimer’s disease. Brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3–5):447–78.

Article  CAS  PubMed  Google Scholar 

Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde. Zeitschrift fuer Psychiatrie. 1907;64:146–9.

Google Scholar 

Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Über eine eigenartige Erkankung der Hirnrinde.” Clin Anat. 1995;8(6):429–31.

Article  CAS  PubMed  Google Scholar 

Foley P. Lipids in Alzheimer’s disease: a century-old story. Biochim Biophys Acta. 2010;1801(8):750–3.

Article  CAS  PubMed  Google Scholar 

Yuan Y, Zhao G, Zhao Y. Dysregulation of energy metabolism in Alzheimer’s disease. J Neurol. 2024;272(1):2.

Article  PubMed  PubMed Central  Google Scholar 

Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Investig. 2012;122(4):1316–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Athauda D, Foltynie T. Insulin resistance and Parkinson’s disease: a new target for disease modification? Prog Neurobiol. 2016;3(145):98–120.

Article  Google Scholar 

Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2):147–52.

Article  CAS  PubMed  Google Scholar 

de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis. 2005;7(1):45–61.

Article  PubMed  Google Scholar 

Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224–43.

Article  CAS  PubMed  Google Scholar 

Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam study. Neurology. 1999;53(9):1937–42.

Article  CAS  PubMed  Google Scholar 

Mehta KM, Ott A, Kalmijn S, Slooter AJ, van Duijn CM, Hofman A, et al. Head trauma and risk of dementia and Alzheimer’s disease: The Rotterdam study. Neurology. 1999;53(9):1959–62.

Article  CAS  PubMed  Google Scholar 

Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology. 2011;77(12):1126–34.

Article  CAS  PubMed  Google Scholar 

Li X, Zeng Z. Exploring the link between estimated glucose disposal rate and Parkinson’s disease: cross-sectional and mortality analysis of NHANES 2003–2016. Front Aging Neurosci. 2025;17:1548020.

Article  PubMed  PubMed Central  Google Scholar 

Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, et al. The impact of type 2 diabetes in Parkinson’s disease. Mov Disord. 2022;37(8):1612–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheong JLY, de Pablo-Fernandez E, Foltynie T, Noyce AJ. The association between type 2 diabetes mellitus and Parkinson’s disease. J Parkinson’s Dis. 2020;24(10):775–89.

Article  Google Scholar 

Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30(4):842–7.

Article  PubMed  Google Scholar 

Kyrtata N, Emsley HCA, Sparasci O, Parkes LM, Dickie BR. A systematic review of glucose transport alterations in Alzheimer’s disease. Front Neurosci. 2021;15:626636.

Article  PubMed  PubMed Central  Google Scholar 

Yanai H, Adachi H, Hakoshima M, Katsuyama H. Pathology and treatments of Alzheimer’s disease based on considering changes in brain energy metabolism due to type 2 diabetes. Molecules. 2024;29(24).

Watson RT, Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res. 2001;56:175–93.

Article  CAS  PubMed  Google Scholar 

Ashrafi G, Wu Z, Farrell RJ, Ryan TA. GLUT4 mobilization supports energetic demands of active synapses. Neuron. 2017;93(3):606-15 e3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Na D, Zhang Z, Meng M, Li M, Gao J, Kong J, et al. Energy metabolism and brain aging: strategies to delay neuronal degeneration. Cell Mol Neurobiol. 2025;45(1):38.

Article  PubMed  PubMed Central  Google Scholar